newsfilter
← Latest News
PR Newswire·

Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD

FDA clearance of the IND enables Eloxx to open U.S. clinical sites for EXPRESS, its global Phase 2 study of exaluren in nonsense-mutation ADPKDEXPRESS will randomize approximately 60 patients 1:1 to exaluren or placebo